Ebola survivors get vaccine booster to ward off return of the virus

NCT ID NCT05992480

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at whether a booster dose of the Ebola vaccine (ERVEBO) can strengthen the immune system of people who have already survived Ebola. Researchers will compare their response to that of healthy people who have never had the virus. The goal is to see if the booster provides lasting protection and is safe for survivors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Ebola virus vaccine (ERVEBO)

What this could lead to

If successful, this could show that a booster shot helps Ebola survivors maintain long-term protection against reinfection.

What could go wrong

This is a small, early-phase study with only 40 participants, so results may not apply broadly. The vaccine may cause side effects like fever or muscle pain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ebola hemorrhagic fever

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kenema Government Hospital

    Kenema, Eastern Province, Sierra Leone